TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study
Background The 18-kDa translocator protein (TSPO) is overexpressed in brain tumours and represents an interesting target for glioma imaging. 18 F-GE-180, a novel TSPO ligand, has shown improved binding affinity and a high target-to-background contrast in patients with glioblastoma. However, the asso...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2020-06, Vol.47 (6), p.1368-1380 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1380 |
|---|---|
| container_issue | 6 |
| container_start_page | 1368 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 47 |
| creator | Unterrainer, M. Fleischmann, D. F. Vettermann, F. Ruf, V. Kaiser, L. Nelwan, D. Lindner, S. Brendel, M. Wenter, V. Stöcklein, S. Herms, J. Milenkovic, V. M. Rupprecht, R. Tonn, J. C. Belka, C. Bartenstein, P. Niyazi, M. Albert, N. L. |
| description | Background
The 18-kDa translocator protein (TSPO) is overexpressed in brain tumours and represents an interesting target for glioma imaging.
18
F-GE-180, a novel TSPO ligand, has shown improved binding affinity and a high target-to-background contrast in patients with glioblastoma. However, the association of uptake characteristics on TSPO PET using
18
F-GE-180 with the histological WHO grade and molecular genetic features so far remains unknown and was evaluated in the current study.
Methods
Fifty-eight patients with histologically validated glioma at initial diagnosis or recurrence were included. All patients underwent
18
F-GE-180 PET, and the maximal and mean tumour-to-background ratios (TBR
max
, TBR
mean
) as well as the PET volume were assessed. On MRI, presence/absence of contrast enhancement was evaluated. Imaging characteristics were correlated with neuropathological parameters (i.e. WHO grade, isocitrate dehydrogenase (
IDH
) mutation, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and telomerase reverse transcriptase (TERT) promoter mutation).
Results
Six of 58 patients presented with WHO grade II, 16/58 grade III and 36/58 grade IV gliomas. An (
IDH
) mutation was found in 19/58 cases, and 39/58 were classified as
IDH
-wild type. High
18
F-GE-180-uptake was observed in all but 4 cases (being WHO grade II glioma,
IDH
-mutant). A high association of
18
F-GE-180-uptake and WHO grades was seen: WHO grade IV gliomas showed the highest uptake intensity compared with grades III and II gliomas (median TBR
max
5.15 (2.59–8.95) vs. 3.63 (1.85–7.64) vs. 1.63 (1.50–3.43),
p
|
| doi_str_mv | 10.1007/s00259-019-04491-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2284850572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2284850572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1975-dac92aa54d4eed5d0f393264ee532b9ed6e09c170616acaaef9e2a7c21be227f3</originalsourceid><addsrcrecordid>eNp9UFtLwzAULqLgnP4BnwK-Wk3Spml8k7FNYbCB8zlkyWnN6JqZtIP9ezMr-ubD4Vz4LpwvSW4JfiAY88eAMWUixSRWnguSsrNkRIq4clyK89-Z48vkKoQtxqSkpRgl_fpttUSr6foedf3O9R7VXhnb1ki1Bu1cA7pvVLxCC53VAdkWfdjQucbVVqumOaIDeFtZMKhurNupJ6SQdt5Dozp7AETKWTqfpqTEJxsUut4cr5OLSjUBbn76OHmfTdeTl3SxnL9OnhepJoKz1CgtqFIsNzmAYQZXmchoEReW0Y0AUwAWmnBckEJppaASQBXXlGyAUl5l4-Ru0N1799lD6OQ2vthGS0lpmZcMM04jig4o7V0IHiq593an_FESLE_xyiFeGeOV3_FKFknZQAoR3Nbg_6T_YX0BepB9KA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2284850572</pqid></control><display><type>article</type><title>TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study</title><source>Springer journals</source><creator>Unterrainer, M. ; Fleischmann, D. F. ; Vettermann, F. ; Ruf, V. ; Kaiser, L. ; Nelwan, D. ; Lindner, S. ; Brendel, M. ; Wenter, V. ; Stöcklein, S. ; Herms, J. ; Milenkovic, V. M. ; Rupprecht, R. ; Tonn, J. C. ; Belka, C. ; Bartenstein, P. ; Niyazi, M. ; Albert, N. L.</creator><creatorcontrib>Unterrainer, M. ; Fleischmann, D. F. ; Vettermann, F. ; Ruf, V. ; Kaiser, L. ; Nelwan, D. ; Lindner, S. ; Brendel, M. ; Wenter, V. ; Stöcklein, S. ; Herms, J. ; Milenkovic, V. M. ; Rupprecht, R. ; Tonn, J. C. ; Belka, C. ; Bartenstein, P. ; Niyazi, M. ; Albert, N. L.</creatorcontrib><description>Background
The 18-kDa translocator protein (TSPO) is overexpressed in brain tumours and represents an interesting target for glioma imaging.
18
F-GE-180, a novel TSPO ligand, has shown improved binding affinity and a high target-to-background contrast in patients with glioblastoma. However, the association of uptake characteristics on TSPO PET using
18
F-GE-180 with the histological WHO grade and molecular genetic features so far remains unknown and was evaluated in the current study.
Methods
Fifty-eight patients with histologically validated glioma at initial diagnosis or recurrence were included. All patients underwent
18
F-GE-180 PET, and the maximal and mean tumour-to-background ratios (TBR
max
, TBR
mean
) as well as the PET volume were assessed. On MRI, presence/absence of contrast enhancement was evaluated. Imaging characteristics were correlated with neuropathological parameters (i.e. WHO grade, isocitrate dehydrogenase (
IDH
) mutation, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and telomerase reverse transcriptase (TERT) promoter mutation).
Results
Six of 58 patients presented with WHO grade II, 16/58 grade III and 36/58 grade IV gliomas. An (
IDH
) mutation was found in 19/58 cases, and 39/58 were classified as
IDH
-wild type. High
18
F-GE-180-uptake was observed in all but 4 cases (being WHO grade II glioma,
IDH
-mutant). A high association of
18
F-GE-180-uptake and WHO grades was seen: WHO grade IV gliomas showed the highest uptake intensity compared with grades III and II gliomas (median TBR
max
5.15 (2.59–8.95) vs. 3.63 (1.85–7.64) vs. 1.63 (1.50–3.43),
p
< 0.001); this association with WHO grades persisted within the
IDH
-wild-type and
IDH
-mutant subgroup analyses (
p
< 0.05). Uptake intensity was also associated with the
IDH
mutational status with a trend towards higher
18
F-GE-180-uptake in
IDH
-wild-type gliomas in the overall group (median TBR
max
4.67 (1.56–8.95) vs. 3.60 (1.50–7.64),
p
= 0.083); however, within each WHO grade, no differences were found (e.g. median TBR
max
in WHO grade III glioma 4.05 (1.85–5.39) vs. 3.36 (2.32–7.64),
p
= 1.000). No association was found between uptake intensity and MGMT or TERT (
p
> 0.05 each).
Conclusion
Uptake characteristics on
18
F-GE-180 PET are highly associated with the histological WHO grades, with the highest
18
F-GE-180 uptake in WHO grade IV glioblastomas and a PET-positive rate of 100% among the investigated high-grade gliomas. Conversely, all TSPO-negative cases were WHO grade II gliomas. The observed association of
18
F-GE-180 uptake and the
IDH
mutational status seems to be related to the high inter-correlation of the
IDH
mutational status and the WHO grades.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-019-04491-5</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Brain cancer ; Brain tumors ; Cardiology ; Correlation analysis ; Deoxyribonucleic acid ; DNA ; DNA methylation ; DNA methyltransferase ; Evaluation ; Fluorine isotopes ; Genetics ; Glioblastoma ; Glioma ; Imaging ; Isocitrate dehydrogenase ; Magnetic resonance imaging ; Medical imaging ; Medicine ; Medicine & Public Health ; Methylguanine ; Mutation ; Neuroimaging ; Neurology ; Nuclear Medicine ; O6-methylguanine-DNA methyltransferase ; Oncology ; Original Article ; Orthopedics ; Positron emission ; Positron emission tomography ; Radiology ; RNA-directed DNA polymerase ; Subgroups ; Target recognition ; Telomerase ; Telomerase reverse transcriptase ; Tomography ; Tumors</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2020-06, Vol.47 (6), p.1368-1380</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1975-dac92aa54d4eed5d0f393264ee532b9ed6e09c170616acaaef9e2a7c21be227f3</citedby><cites>FETCH-LOGICAL-c1975-dac92aa54d4eed5d0f393264ee532b9ed6e09c170616acaaef9e2a7c21be227f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-019-04491-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-019-04491-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids></links><search><creatorcontrib>Unterrainer, M.</creatorcontrib><creatorcontrib>Fleischmann, D. F.</creatorcontrib><creatorcontrib>Vettermann, F.</creatorcontrib><creatorcontrib>Ruf, V.</creatorcontrib><creatorcontrib>Kaiser, L.</creatorcontrib><creatorcontrib>Nelwan, D.</creatorcontrib><creatorcontrib>Lindner, S.</creatorcontrib><creatorcontrib>Brendel, M.</creatorcontrib><creatorcontrib>Wenter, V.</creatorcontrib><creatorcontrib>Stöcklein, S.</creatorcontrib><creatorcontrib>Herms, J.</creatorcontrib><creatorcontrib>Milenkovic, V. M.</creatorcontrib><creatorcontrib>Rupprecht, R.</creatorcontrib><creatorcontrib>Tonn, J. C.</creatorcontrib><creatorcontrib>Belka, C.</creatorcontrib><creatorcontrib>Bartenstein, P.</creatorcontrib><creatorcontrib>Niyazi, M.</creatorcontrib><creatorcontrib>Albert, N. L.</creatorcontrib><title>TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Background
The 18-kDa translocator protein (TSPO) is overexpressed in brain tumours and represents an interesting target for glioma imaging.
18
F-GE-180, a novel TSPO ligand, has shown improved binding affinity and a high target-to-background contrast in patients with glioblastoma. However, the association of uptake characteristics on TSPO PET using
18
F-GE-180 with the histological WHO grade and molecular genetic features so far remains unknown and was evaluated in the current study.
Methods
Fifty-eight patients with histologically validated glioma at initial diagnosis or recurrence were included. All patients underwent
18
F-GE-180 PET, and the maximal and mean tumour-to-background ratios (TBR
max
, TBR
mean
) as well as the PET volume were assessed. On MRI, presence/absence of contrast enhancement was evaluated. Imaging characteristics were correlated with neuropathological parameters (i.e. WHO grade, isocitrate dehydrogenase (
IDH
) mutation, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and telomerase reverse transcriptase (TERT) promoter mutation).
Results
Six of 58 patients presented with WHO grade II, 16/58 grade III and 36/58 grade IV gliomas. An (
IDH
) mutation was found in 19/58 cases, and 39/58 were classified as
IDH
-wild type. High
18
F-GE-180-uptake was observed in all but 4 cases (being WHO grade II glioma,
IDH
-mutant). A high association of
18
F-GE-180-uptake and WHO grades was seen: WHO grade IV gliomas showed the highest uptake intensity compared with grades III and II gliomas (median TBR
max
5.15 (2.59–8.95) vs. 3.63 (1.85–7.64) vs. 1.63 (1.50–3.43),
p
< 0.001); this association with WHO grades persisted within the
IDH
-wild-type and
IDH
-mutant subgroup analyses (
p
< 0.05). Uptake intensity was also associated with the
IDH
mutational status with a trend towards higher
18
F-GE-180-uptake in
IDH
-wild-type gliomas in the overall group (median TBR
max
4.67 (1.56–8.95) vs. 3.60 (1.50–7.64),
p
= 0.083); however, within each WHO grade, no differences were found (e.g. median TBR
max
in WHO grade III glioma 4.05 (1.85–5.39) vs. 3.36 (2.32–7.64),
p
= 1.000). No association was found between uptake intensity and MGMT or TERT (
p
> 0.05 each).
Conclusion
Uptake characteristics on
18
F-GE-180 PET are highly associated with the histological WHO grades, with the highest
18
F-GE-180 uptake in WHO grade IV glioblastomas and a PET-positive rate of 100% among the investigated high-grade gliomas. Conversely, all TSPO-negative cases were WHO grade II gliomas. The observed association of
18
F-GE-180 uptake and the
IDH
mutational status seems to be related to the high inter-correlation of the
IDH
mutational status and the WHO grades.</description><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>Cardiology</subject><subject>Correlation analysis</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>DNA methyltransferase</subject><subject>Evaluation</subject><subject>Fluorine isotopes</subject><subject>Genetics</subject><subject>Glioblastoma</subject><subject>Glioma</subject><subject>Imaging</subject><subject>Isocitrate dehydrogenase</subject><subject>Magnetic resonance imaging</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methylguanine</subject><subject>Mutation</subject><subject>Neuroimaging</subject><subject>Neurology</subject><subject>Nuclear Medicine</subject><subject>O6-methylguanine-DNA methyltransferase</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Radiology</subject><subject>RNA-directed DNA polymerase</subject><subject>Subgroups</subject><subject>Target recognition</subject><subject>Telomerase</subject><subject>Telomerase reverse transcriptase</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UFtLwzAULqLgnP4BnwK-Wk3Spml8k7FNYbCB8zlkyWnN6JqZtIP9ezMr-ubD4Vz4LpwvSW4JfiAY88eAMWUixSRWnguSsrNkRIq4clyK89-Z48vkKoQtxqSkpRgl_fpttUSr6foedf3O9R7VXhnb1ki1Bu1cA7pvVLxCC53VAdkWfdjQucbVVqumOaIDeFtZMKhurNupJ6SQdt5Dozp7AETKWTqfpqTEJxsUut4cr5OLSjUBbn76OHmfTdeTl3SxnL9OnhepJoKz1CgtqFIsNzmAYQZXmchoEReW0Y0AUwAWmnBckEJppaASQBXXlGyAUl5l4-Ru0N1799lD6OQ2vthGS0lpmZcMM04jig4o7V0IHiq593an_FESLE_xyiFeGeOV3_FKFknZQAoR3Nbg_6T_YX0BepB9KA</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Unterrainer, M.</creator><creator>Fleischmann, D. F.</creator><creator>Vettermann, F.</creator><creator>Ruf, V.</creator><creator>Kaiser, L.</creator><creator>Nelwan, D.</creator><creator>Lindner, S.</creator><creator>Brendel, M.</creator><creator>Wenter, V.</creator><creator>Stöcklein, S.</creator><creator>Herms, J.</creator><creator>Milenkovic, V. M.</creator><creator>Rupprecht, R.</creator><creator>Tonn, J. C.</creator><creator>Belka, C.</creator><creator>Bartenstein, P.</creator><creator>Niyazi, M.</creator><creator>Albert, N. L.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20200601</creationdate><title>TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study</title><author>Unterrainer, M. ; Fleischmann, D. F. ; Vettermann, F. ; Ruf, V. ; Kaiser, L. ; Nelwan, D. ; Lindner, S. ; Brendel, M. ; Wenter, V. ; Stöcklein, S. ; Herms, J. ; Milenkovic, V. M. ; Rupprecht, R. ; Tonn, J. C. ; Belka, C. ; Bartenstein, P. ; Niyazi, M. ; Albert, N. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1975-dac92aa54d4eed5d0f393264ee532b9ed6e09c170616acaaef9e2a7c21be227f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>Cardiology</topic><topic>Correlation analysis</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>DNA methyltransferase</topic><topic>Evaluation</topic><topic>Fluorine isotopes</topic><topic>Genetics</topic><topic>Glioblastoma</topic><topic>Glioma</topic><topic>Imaging</topic><topic>Isocitrate dehydrogenase</topic><topic>Magnetic resonance imaging</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methylguanine</topic><topic>Mutation</topic><topic>Neuroimaging</topic><topic>Neurology</topic><topic>Nuclear Medicine</topic><topic>O6-methylguanine-DNA methyltransferase</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Radiology</topic><topic>RNA-directed DNA polymerase</topic><topic>Subgroups</topic><topic>Target recognition</topic><topic>Telomerase</topic><topic>Telomerase reverse transcriptase</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Unterrainer, M.</creatorcontrib><creatorcontrib>Fleischmann, D. F.</creatorcontrib><creatorcontrib>Vettermann, F.</creatorcontrib><creatorcontrib>Ruf, V.</creatorcontrib><creatorcontrib>Kaiser, L.</creatorcontrib><creatorcontrib>Nelwan, D.</creatorcontrib><creatorcontrib>Lindner, S.</creatorcontrib><creatorcontrib>Brendel, M.</creatorcontrib><creatorcontrib>Wenter, V.</creatorcontrib><creatorcontrib>Stöcklein, S.</creatorcontrib><creatorcontrib>Herms, J.</creatorcontrib><creatorcontrib>Milenkovic, V. M.</creatorcontrib><creatorcontrib>Rupprecht, R.</creatorcontrib><creatorcontrib>Tonn, J. C.</creatorcontrib><creatorcontrib>Belka, C.</creatorcontrib><creatorcontrib>Bartenstein, P.</creatorcontrib><creatorcontrib>Niyazi, M.</creatorcontrib><creatorcontrib>Albert, N. L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Unterrainer, M.</au><au>Fleischmann, D. F.</au><au>Vettermann, F.</au><au>Ruf, V.</au><au>Kaiser, L.</au><au>Nelwan, D.</au><au>Lindner, S.</au><au>Brendel, M.</au><au>Wenter, V.</au><au>Stöcklein, S.</au><au>Herms, J.</au><au>Milenkovic, V. M.</au><au>Rupprecht, R.</au><au>Tonn, J. C.</au><au>Belka, C.</au><au>Bartenstein, P.</au><au>Niyazi, M.</au><au>Albert, N. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><date>2020-06-01</date><risdate>2020</risdate><volume>47</volume><issue>6</issue><spage>1368</spage><epage>1380</epage><pages>1368-1380</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Background
The 18-kDa translocator protein (TSPO) is overexpressed in brain tumours and represents an interesting target for glioma imaging.
18
F-GE-180, a novel TSPO ligand, has shown improved binding affinity and a high target-to-background contrast in patients with glioblastoma. However, the association of uptake characteristics on TSPO PET using
18
F-GE-180 with the histological WHO grade and molecular genetic features so far remains unknown and was evaluated in the current study.
Methods
Fifty-eight patients with histologically validated glioma at initial diagnosis or recurrence were included. All patients underwent
18
F-GE-180 PET, and the maximal and mean tumour-to-background ratios (TBR
max
, TBR
mean
) as well as the PET volume were assessed. On MRI, presence/absence of contrast enhancement was evaluated. Imaging characteristics were correlated with neuropathological parameters (i.e. WHO grade, isocitrate dehydrogenase (
IDH
) mutation, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and telomerase reverse transcriptase (TERT) promoter mutation).
Results
Six of 58 patients presented with WHO grade II, 16/58 grade III and 36/58 grade IV gliomas. An (
IDH
) mutation was found in 19/58 cases, and 39/58 were classified as
IDH
-wild type. High
18
F-GE-180-uptake was observed in all but 4 cases (being WHO grade II glioma,
IDH
-mutant). A high association of
18
F-GE-180-uptake and WHO grades was seen: WHO grade IV gliomas showed the highest uptake intensity compared with grades III and II gliomas (median TBR
max
5.15 (2.59–8.95) vs. 3.63 (1.85–7.64) vs. 1.63 (1.50–3.43),
p
< 0.001); this association with WHO grades persisted within the
IDH
-wild-type and
IDH
-mutant subgroup analyses (
p
< 0.05). Uptake intensity was also associated with the
IDH
mutational status with a trend towards higher
18
F-GE-180-uptake in
IDH
-wild-type gliomas in the overall group (median TBR
max
4.67 (1.56–8.95) vs. 3.60 (1.50–7.64),
p
= 0.083); however, within each WHO grade, no differences were found (e.g. median TBR
max
in WHO grade III glioma 4.05 (1.85–5.39) vs. 3.36 (2.32–7.64),
p
= 1.000). No association was found between uptake intensity and MGMT or TERT (
p
> 0.05 each).
Conclusion
Uptake characteristics on
18
F-GE-180 PET are highly associated with the histological WHO grades, with the highest
18
F-GE-180 uptake in WHO grade IV glioblastomas and a PET-positive rate of 100% among the investigated high-grade gliomas. Conversely, all TSPO-negative cases were WHO grade II gliomas. The observed association of
18
F-GE-180 uptake and the
IDH
mutational status seems to be related to the high inter-correlation of the
IDH
mutational status and the WHO grades.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00259-019-04491-5</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2020-06, Vol.47 (6), p.1368-1380 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_journals_2284850572 |
| source | Springer journals |
| subjects | Brain cancer Brain tumors Cardiology Correlation analysis Deoxyribonucleic acid DNA DNA methylation DNA methyltransferase Evaluation Fluorine isotopes Genetics Glioblastoma Glioma Imaging Isocitrate dehydrogenase Magnetic resonance imaging Medical imaging Medicine Medicine & Public Health Methylguanine Mutation Neuroimaging Neurology Nuclear Medicine O6-methylguanine-DNA methyltransferase Oncology Original Article Orthopedics Positron emission Positron emission tomography Radiology RNA-directed DNA polymerase Subgroups Target recognition Telomerase Telomerase reverse transcriptase Tomography Tumors |
| title | TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T20%3A54%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TSPO%20PET,%20tumour%20grading%20and%20molecular%20genetics%20in%20histologically%20verified%20glioma:%20a%20correlative%2018F-GE-180%20PET%20study&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Unterrainer,%20M.&rft.date=2020-06-01&rft.volume=47&rft.issue=6&rft.spage=1368&rft.epage=1380&rft.pages=1368-1380&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-019-04491-5&rft_dat=%3Cproquest_cross%3E2284850572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2284850572&rft_id=info:pmid/&rfr_iscdi=true |